REACTIVAS

  • Research type

    Research Study

  • Full title

    Subclinical cytomegalovirus reactivation in patients with newly diagnosed or relapsed ANCA-associated vasculitis and adverse clinical outcomes

  • IRAS ID

    294850

  • Contact name

    Dimitrios Chanouzas

  • Contact email

    Dimitrios.Chanouzas@uhb.nhs.uk

  • Sponsor organisation

    University Hospitals Birmingham

  • Duration of Study in the UK

    3 years, 0 months, 0 days

  • Research summary

    This study will investigate how common it is to develop reactivation of previous Cytomegalovirus (CMV) infection in patients with newly diagnosed or recently relapsed anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We will then look to see what affect CMV reactivation has on various outcomes including the severity of vasculitis, the response to treatment and the damage caused by vasculitis. Our research has recently shown that asymptomatic reactivation of CMV is a frequent event in AAV patients, occurring in roughly 25% of AAV patients in remission. We already know that reactivation of CMV infection in patients with AAV is associated with poorer outcomes such as reduced kidney function, increased risk of infection and death, increased risk of blood clots and increased stiffness of the blood vessels, which is a risk factor for heart disease and stroke.

    If CMV reactivation is common and causes significant complications, this study may then lead on to future research involving treatment to prevent CMV reactivation.

    We will be looking to recruit patients under the care of the Queen Elizabeth Hospital with newly diagnosed or recently relapsed AAV in the last 2 weeks who are positive for previous CMV infection.

    We will follow these patients up with 10 visits over 12 months; where possible these will coincide with their usual vasculitis clinic appointments. At each visit the participants will be required to give blood and urine samples and answer questions related to their vasculitis.

  • REC name

    London - Camden & Kings Cross Research Ethics Committee

  • REC reference

    22/PR/0010

  • Date of REC Opinion

    24 Jan 2022

  • REC opinion

    Further Information Favourable Opinion